Cowen Raises Sage Value On New Phase 2 Trial Success By: Benzinga via Benzinga December 07, 2017 at 14:41 PM EST SAGE Therapeutics Inc (NASDAQ: SAGE) released Thursday positive top-line data from its Phase 2 study of SAGE-217 in major depressive ... Read More >> Related Stocks: Sage Therapeutic Com